Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor Burde
- Conditions
- Follicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated)MedDRA version: 21.1Level: PTClassification code 10016908Term: Follicle centre lymphoma, follicular grade I, II, III stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10016909Term: Follicle centre lymphoma, follicular grade I, II, III stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10016910Term: Follicle centre lymphoma, follicular grade I, II, III stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2018-004038-13-DE
- Lead Sponsor
- Klinikum der Universität München
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 102
- Histologically confirmed follicular lymphoma grade 1, 2 or 3A with a biopsy performed within 12 months before study entry and with material available for central review and complementary scientific analyses
- Ann Arbor stage III/IV, or stage II not suitable for radiotherapy, or stage II bulky disease
- Age = 18 years
- No prior lymphoma therapy
- Need for start of therapy as defined by at least one of the following criteria:
bulky disease at study entry according to the GELF criteria (nodal or extranodal mass > 7 cm in its greater diameter)
B symptoms (fever, drenching night sweats, or unintentional weight loss of > 10% of normal body weight over a period of 6 months or less)
hematopoietic insufficiency (granulocytopenia < 1500/µl, Hb < 10 g/dl,
thrombocytopenia < 100000/µl)
compressive syndrome or high risk for compression syndrome
pleural/peritoneal effusion
symptomatic extranodal manifestations
- At least one bi-dimensionally measurable lesion (> 2 cm in its largest dimension by CT
scan or MRI)
- Performance status = 2 on the ECOG scale
- Adequate hematologic function (unless abnormalities are related to NHL),
defined as follows:
Hemoglobin = 9.0 g/dL
absolute neutrophil count = 1500/µl
Platelet count = 75000/µl
- Women are not breast feeding, are using highly effective contraception (see section 11.4.1), are not pregnant, and
agree not to become pregnant during study treatment and for 18 months after last application of Obinutuzumab and for one month after last application of Copanlisib (pregnancy testing is mandatory for premenopausal women).
- Men agree not to father a child during study treatment and for 18 months after last application of Obinutuzumab and for one month after last application of Copanlisib.
- Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 58
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 40
- Transformation to high-grade lymphoma (secondary to low grade” FL)
- Grade 3B follicular lymphoma
- Presence or history of CNS disease (either CNS lymphoma or leptomeningeal lymphoma)
- Known hypersensitivity to any of the study drugs
- Known sensitivity to murine products
- Patients with HbA1c > 8.5 % at Screening
- Uncontrolled arterial hypertension despite optimal medical management (per investigator’s assessment)
- Regular use of corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 20 mg/day prednisone or administered as prephase treatment according to study protocol (see section 7.2 of study protocol)
- Concomitant use of strong CYP3A4 inhibitors and/or inducers
- Prior or concomitant malignancies except:
non-melanoma skin cancer or adequately treated in carcinoma in situ of the cervix
other malignant diseases not specified above which have been curatively treated by surgery alone and from which subject is disease-free for = 5 years without further treatment
- Serious disease interfering with a regular therapy according to the study protocol:
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined
by the New York Heart Association Functional Classification
pulmonary (e.g. chronic lung disease with hypoxemia)
endocrine (e.g. severe, not sufficiently controlled diabetes mellitus)
renal insufficiency (unless caused by the lymphoma): creatinine > 2x normal value and/or creatinine clearance < 50 ml/min)
impairment of liver function (unless caused by the lymphoma): transaminases > 3x
normal or bilirubin > 2.0 mg/dl (unless caused by known Morbus Meulengracht
[Gilbert-Meulengracht-Syndrome])
- Positive test results for chronic HBV infection (defined as positive HBsAg serology)
Patients with occult or prior HBV infection (defined as negative HBsAg and positive total
HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to
undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface
antibody (HBsAb) after vaccination or prior but cured hepatitis B are eligible.
- Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing)
Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
- Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
- Known history of HIV seropositive status
- Patients with a history of confirmed PML
- Vaccination with a live vaccine within 28 days prior to registration
- Recent major surgery (within 4 weeks prior to the start of Cycle 1)
- History of stroke or intracranial hemorrhage within 6 months prior to registration
- Serious underlying medical conditions, which could impair the ability of the patient to
undergo the treatment offered in the study (e.g. ongoing infection, gastric ulcers, active
autoimmune disease)
- Treatment within a clinical study within 30 days prior to study entry
- Prior organ, bone marrow, or peripheral blood stem cell transplantation
- Known or persistent abuse of medication, drugs, or alcohol
- Any other co-existing medical or psychological condition that will preclude participation in
the study or compromise ability to give informed consent
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method